Ratings SKAN Group AG

Equities

SKAN

CH0013396012

Market Closed - Swiss Exchange Other stock markets 11:31:55 2024-05-08 am EDT			5-day change	1st Jan Change
81.4 ^CHF	-0.97%		-1.33%	+0.74%

Mar. 26	Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024
Mar. 26	Switzerland's SKAN Group Logs Improved FY23 Profit, Revenue	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Sales forecast by analysts have been recently revised upwards.

Weaknesses

With an expected P/E ratio at 45.54 and 33.97 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 4.43 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SKAN GROUP AG	+0.74%	2.04B	-
SHOCKWAVE MEDICAL, INC.	+73.43%	12.41B	B-
PENUMBRA, INC.	-19.82%	8.14B	C+
MASIMO CORPORATION	+3.38%	7.2B	C-
GETINGE AB	+3.66%	5.93B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.89%	5.43B	D+
APT MEDICAL INC.	+37.45%	4.89B	-
ASAHI INTECC CO., LTD.	-19.82%	4.09B	B-
INARI MEDICAL, INC.	-35.47%	2.49B	C
SHENZHEN YHLO BIOTECH CO., LTD.	+9.36%	1.98B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes